Anupam Basuray, MD
Advanced Heart Failure and Transplant Cardiology · Columbus, OHNPI 1659536894
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,991 of the $5,746 with a category attached, or 69.5%. 16 manufacturers reported payments, led by Abbott at 36.2% of the total. Reporting peaked in 2020 at $1,594 and has fallen 89.0% since, to $176 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in OH, where the typical reported total is $4,421.
Across 81 payments — averaging $70.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Pfizer$2K
- Cvrx, Inc.$410
- Actelion Pharmaceuticals US, Inc.$347
- Abiomed$323
- E.r. Squibb & Sons, L.L.C.$177
- plus $836 from 10 others
Across 56 payments — averaging $17,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$878K
- Abbott$112K
- Amgen$86
What the payments were for
- Speaking & faculty fees$1,57527%
- Travel & lodging$170%
- Food & beverage$3,99169%
- Education$1633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 42 | $2,078 |
| Pfizer | 1 | $1,575 |
| Cvrx, Inc. | 6 | $410 |
| Actelion Pharmaceuticals US, Inc. | 6 | $347 |
| Abiomed | 4 | $323 |
| E.r. Squibb & Sons, L.L.C. | 4 | $177 |
| Astellas Pharma US Inc | 2 | $150 |
| W. L. Gore & Associates, Inc. | 1 | $136 |
| United Therapeutics Corporation | 1 | $132 |
| Boston Scientific | 2 | $115 |
| Medtronic | 2 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $58 |
| Kestra Medical Technology Services, Inc. | 1 | $45 |
| Davol Inc. | 1 | $37 |
| AstraZeneca | 2 | $32 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$1,575
- HeartMate 3 Left Ventricular Dev$529
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$417
- Barostim Neo System$367
- OPSUMIT$226
- GORE VIABAHN VBX Balloon Expandable Endo$136
- CARDIOMEMS$135
- TYVASO$132
- REMODULIN$132
- ORENITRAM$132
- Impella$128
- CAMZYOS$126
- CardioMEMS HF System$125
- UPTRAVI$110
How this compares
$5,746 in reported general payments places this provider in the 50th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 80 | $1,986,745 |
| VyndaqelTafamidis Meglumine | 34 | $744,220 |
| EntrestoSacubitril/Valsartan | 307 | $320,021 |
| FarxigaDapagliflozin Propanediol | 187 | $173,050 |
| JardianceEmpagliflozin | 109 | $126,228 |
| EliquisApixaban | 96 | $107,711 |
| WegovySemaglutide | 14 | $18,687 |
| CorlanorIvabradine Hcl | 14 | $8,487 |
| Metoprolol Succinate | 307 | $4,637 |
| Torsemide | 216 | $4,543 |
| Bumetanide | 64 | $3,391 |
| Potassium Chloride | 103 | $2,229 |
| Spironolactone | 343 | $1,934 |
| Isosorbide Dinitrate | 16 | $1,785 |
| Ranolazine ErRanolazine | 14 | $1,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $1,575 | $2,838,676210 claims |
| AstraZenecaFarxiga | $32 | $173,050187 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Columbus
- William AbrahamColumbus$802K
- Rami KahwashColumbus$379K
- Beth ForemanColumbus$28K
- Vaiibhav PatelColumbus$10K
- Ray HershbergerColumbus$6K
- Ajay VallakatiColumbus$4K
- Katherine DoddColumbus$4K
- Lindsay CastleColumbus$3K
- Rodolfo Denadai BenattiColumbus$2K
- Yaquta KakaColumbus$859
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.